Nazila Deznabi
1 
, Nasrin Abolhasanpour
2* , Hanieh Salehi-Pourmehr
21 Shams Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
2 Research Center for Evidence-Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
The Chinese Sinopharm vaccine was produced in 2020 as an effective preventive measure against COVID-19. The low and non-serious adverse effects of the Sinopharm COVID-19 vaccine were reported in the literature. This report presents a 70-year-old man who underwent surgical burr-hole evacuation of the hematoma in the right and left parietal and frontal areas. Six days after discharge from the hospital, he received Sinopharm vaccine, and three days post-vaccination, he was referred to the hospital with signs of weakness and lethargy. During the hospitalization, the patient had extensive tonic-clonic seizures and then went into a coma. A close follow-up was done for clinical, laboratory, and imaging studies during his stay in the hospital. After 10 days of appropriate medication, the seizure stopped.